Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17871698 | 0.98 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2ALDH1A3MAPTTP53 | |
| SCHEMBL19601711 | 0.85 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ALDH1A3MAPTHPGD | |
| SCHEMBL28621356 | 0.85 | HTR1A (0.51) | CYP1A2CYP2C9 | |
| SCHEMBL16577084 | 0.85 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2ALDH1A3TDP1LMNA | |
| SCHEMBL20424744 | 0.84 | ALDH1A3 (0.57) | ALDH1A1SMN1; SMN2ALDH1A3MAPTTP53 | |
| SCHEMBL20018697 | 0.83 | MAPT (0.49) | ALDH1A1SMN1; SMN2MAPTTP53HPGD | |
| SCHEMBL25691836 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ALDH1A3MAPTMAPK1 | |
| SCHEMBL17871811 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL25487206 | 0.81 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL19584987 | 0.79 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2ALDH1A3MAPTTRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-11702393-B2 | Synthesis of a monoacylglycerol lipase inhibitor | H. LUNDBECK A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| CN-110437236-B | Indole-1, 2-and 1, 4-benzodiazepine compound and synthetic method thereof | 青岛农业大学 | 2020-08-18 | — | — | CN | disclosed |
| CN-108640918-B | Synthetic method of nitrogen heterocyclic ring substituted p-quinone skeleton spiro-compound | 青岛农业大学 | 2020-05-19 | — | — | CN | disclosed |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-9957242-B2 | Carbamate compounds and methods of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-03-16 | — | — | US | disclosed |
| US-9487495-B2 | Carbamate compounds and of making and using same | THE SCRIPTS RESEARCH INSTITUTE (US) | 2016-11-08 | — | — | US | disclosed |
| US-9133148-B2 | Carbamate compounds and of making and using same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | ALDH1A1 118/4885SMN1; SMN2 3772/4885ALDH1A3 693/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | ALDH1A1 2448/4885SMN1; SMN2 3430/4885ALDH1A3 2923/4885 |
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | ALDH1A1 1712/4885SMN1; SMN2 1553/4885ALDH1A3 1213/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | ALDH1A1 2487/4885SMN1; SMN2 2374/4885ALDH1A3 1192/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | ALDH1A1 2260/4885SMN1; SMN2 3564/4885ALDH1A3 2633/4885 |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, ACSL6 | ALDH1A1 932/4885SMN1; SMN2 1888/4885ALDH1A3 685/4885 |
| US-20150148330-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABHD6, ABHD16A, PRMT6 | ALDH1A1 2002/4885SMN1; SMN2 1644/4885ALDH1A3 1270/4885 |
| US-20170073320-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | ALDH1A1 1712/4885SMN1; SMN2 1553/4885ALDH1A3 1213/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | ALDH1A1 932/4885SMN1; SMN2 1888/4885ALDH1A3 685/4885 |
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | ALDH1A1 4349/4885SMN1; SMN2 1770/4885ALDH1A3 4045/4885 |
| US-11702393-B2 | Synthesis of a monoacylglycerol lipase inhibitor | MGLL, PNLIP, LPL | ALDH1A1 1148/4885SMN1; SMN2 3547/4885ALDH1A3 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.